ANNUAL REPORT
2020
Association for Molecular Pathology
Contents

2 Message from AMP’s Executive Director

3 AMP Strategic Plan: Mission Statement, Vision Statement & Core Principles

5 2020 Board of Directors & Committee Chairs

6 Organizational Relationships & International Affiliates

7 Advancing Molecular Medicine

8 Innovation & Improved Patient Care

9 Membership and Annual Meeting Overview

10 Education Initiatives

11 Financial Statement
Dear Colleagues,

It is impossible to reflect on 2020 without honoring the people lost and lives radically changed due to SARS-CoV-2, the virus that has caused the COVID-19 pandemic.

Just weeks after our joyous celebrations at the 25th AMP Annual Meeting & Expo in November 2019, AMP members became some of the first individuals to grasp the ramifications novel coronavirus’ posed for our interconnected world. Our community is serving on the front lines of the pandemic, developing and ramping up testing for COVID-19 despite legislative red tape, supply chain issues and staffing shortages. All of this was accomplished while clinical laboratory professionals continued to conduct routine testing for other medical concerns.

The critical importance of molecular diagnostics’ impact on patient care and public health were demonstrated on a global stage in 2020. I thank each and everyone of you for your resourcefulness, sacrifices, and service this year. Please know that your dedication to helping patients serves as inspiration and hope to many as the fight against COVID-19 continues.

On behalf of AMP’s Board of Directors, volunteers and staff, I wish you good health and that we can see each other again soon.

Mary Steele Williams, MNA, MT(ASCP)SM, CAE
AMP Executive Director
AMP’s strategic plan is dynamic. Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP’s Mission, Vision, and Core Principles.

The Association For Molecular Pathology is a not-for-profit scientific society that advances the Clinical Practice, Science, and Excellence of molecular and genomic laboratory medicine through Education, Innovation, and Advocacy to enable highest quality health care.
Mission
Vision
Principles

Core
Principles

The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care.

- Quality Health Care Through Excellence in Clinical Molecular Testing
- Fostering the Global Community of Molecular Pathology Professionals
- Collaboration to Advance Molecular Pathology
- Advocacy that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- Innovation to Transform Patient Care
2020 Board of Directors & Committee Chairs

President – Karen Weck, MD

President-Elect; Awards and Strategic Opportunities Committee Chair – Antonia R. Sepulveda, MD, PhD

Past President and Nominating Committee Chair – Victoria M. Pratt, PhD

Secretary-Treasurer and Finance Committee Chair – Betsy A. Bove, PhD

Clinical Practice Committee Chair – Dan Jones, MD, PhD

Economic Affairs Committee Chair – Samuel K. Caughron, MD

International Affairs Committee – Rami Mahfouz, MD, MPH

Membership Affairs Committee Chair – Midhat S. Farooqi, MD, PhD

Professional Relations Committee Chair – Jordan Laser, MD

Program Committee Chair – Jane Gibson, PhD

Publications Committee – Larissa V. Furtado, MD

Training & Education Committee Chair – Nathanael Bailey, MD*

Genetics Subdivision Chair – Thomas W. Prior, PhD

Hematopathology Subdivision Chair – Maria E. Arcila, MD

Infectious Diseases Subdivision Chair – Frederick S. Nolte, PhD

Informatics Subdivision Chair – Somak Roy, MD

Solid Tumors Subdivision Chair – Lawrence J. Jennings, MD, PhD

Executive Director – Mary Steele Williams, MNA, MT(ASCP)SM, CAE

* Assumed role August 2020; previously held by Yassmine Akkari, PhD
Organizational Relationships

**AMP maintains membership in the following organizations:**
- The Pathology Roundtable
- Blood PAC
- Cancer Leadership Council (CLC)
- Federation of American Societies for Experimental Biology (FASEB)
- Global Alliance for Genomic Medicine
- Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- Intersociety Pathology Council (IPC)
- Personalized Medicine Coalition (PMC)
- Associate Member of the Intersociety Council for Pathology Information (ICPI)

**AMP maintains relationships with the following groups:**
- Representative to ASCO CancerLinQ Steering Committee
- Cooperating Society of the American Board of Pathology (ABP)
- Steering Committee, NIST Genome in A Bottle Consortium
- Sponsor of the National Academies Roundtable on Genomics and Precision Health
- Representatives to FNIH Biomarkers Consortium Steering Committees
- Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
- Representative to the CAP Molecular Oncology Committee

International Affiliates:
- The Hong Kong Society for Molecular Diagnostic Sciences
- The Korean Society for Laboratory Medicine
- The Molecular Pathology Association of India
- The German Society of Pathology
- Brazilian Society of Clinical Pathology and Laboratory Medicine
- The Italian Society of Pathology and Translational Medicine
- American University of Beirut Medical Center
- Middle East Molecular Biology Sources
To assess the “situation on the ground” during the early days of the pandemic, AMP facilitated two groundbreaking surveys of U.S. clinical laboratory professionals around the country. This data, combined with ongoing engagement, contributed to a 300% increase in media requests.

Finally, much as our members’ other responsibilities continued during the pandemic, so too did AMP’s advocacy efforts on economic issues, diversity and anti-discrimination in science, and data management. For a full overview, please visit our Position Statements & Letters webpage.

The advocacy of AMP members yielded a tremendous impact in shaping conversations and policies on U.S. COVID-19 testing in 2020, including:

• Endorsing the VITAL Act legislation sponsored by Senator Rand Paul (crafted with direct input from AMP subject matter experts)
• Closing coverage gaps for clinical laboratory testing of SARS-CoV-2 through legislation such as the Families First Coronavirus Act
• Helping to shape the coding, coverage, and reimbursement of SARS-CoV-2 molecular diagnostic tests
AMP published one clinical practice guideline in 2020, and supported numerous member-led efforts to publish insightful analyses of the missteps that took place in the early months of the U.S. outbreak, as well as provide recommendations for improving the nation’s response to future pandemics.

July; 22 (7): 847-859

In addition, AMP maintained a robust COVID-19 resources webpage, which continues to support the clinical laboratory community as the pandemic continues. To increase subdivision-specific education and engagement, AMP launched the “Subdivision Spotlight” newsletter series, which are sent twice a year to the members of each of AMP’s five subdivisions (ten issues per year).
Total AMP membership grew for the 14th year in a row in 2020, rising to 2,553 members, up from 2,522 in 2019. The Board of Directors also decided to grant free Associate Membership to all qualifying students, residents and postdocs, beginning in 2021, which will make membership accessible to an even broader global community in the future. AMP members can be found in 57 countries.

Due to COVID-19 travel restrictions, our AMP Europe meeting was delayed until 2021, and the AMP Annual Meeting & Expo pivoted to an online education and networking experience. Despite these challenges, we welcomed more than 1,700 of the world’s leading molecular professionals and 139 exhibiting companies to our virtual event, which featured over 50 educational sessions, nearly 300 poster presentations, 75 corporate workshops, and many cutting-edge lectures and plenary sessions focusing on major areas of clinical molecular diagnostics.

We look forward to welcoming attendees and exhibitors back to in-person events as soon as safely feasible.
AMP’s education initiatives continue to reach a global audience despite overwhelming challenges posed by the COVID-19 pandemic. The AMP Europe meeting was postponed due to the pandemic, and will be hosted virtually in 2021. However, AMP achieved great success in launching and continuing multiple grant-supported programs and webinar series in 2020, including Emerging and Evolving Biomarkers, a Laboratory Management Certificate Program, NGS 101 v2.0, and more.

By moving to a new learning management system this past June, AMP was also able to begin providing new tools and educational modalities, such as flash cards and question banks, to both members and non-members. The AMP learning management system, AMPED™, has more than 220 hours of cutting-edge molecular pathology content delivered by experts in the field. To learn more, visit educate.amp.org.
# Financial Statement

## Strategic Initiative Revenue Over Expenses

<table>
<thead>
<tr>
<th>STRATEGIC INITIATIVE</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advocacy</td>
<td>$(480,376)</td>
<td>$(612,500)</td>
<td>$(490,772)</td>
</tr>
<tr>
<td>Communications &amp; Outreach</td>
<td>$(140,059)</td>
<td>$(149,155)</td>
<td>$(125,071)</td>
</tr>
<tr>
<td>Education</td>
<td>$370,854</td>
<td>$1,832,607</td>
<td>$2,021,273</td>
</tr>
<tr>
<td>Innovation &amp; Improved Patient Care</td>
<td>$(369,395)</td>
<td>$(209,091)</td>
<td>$(250,296)</td>
</tr>
<tr>
<td>Membership &amp; Management Services</td>
<td>$140,944</td>
<td>$76,388</td>
<td>$220,128</td>
</tr>
</tbody>
</table>

## Excess Revenue Over Expenses

<table>
<thead>
<tr>
<th>EXCESS REVENUE OVER EXPENSES</th>
<th>2020</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$478,031</td>
<td>$704,474</td>
<td>$935,006</td>
</tr>
</tbody>
</table>